Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
1996 Jan 5
Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells
33)20-13(24)7-5-8-14(20)25
and 10 mg/kg) is subjected to electrolytic injury of the coronary artery
GSK-2606414 - CAS# 1337531-36-8 0435 1996 Jan 5GSK 2606414, CAS No. 1337531 36 8, is an orally available, potent, and selective PERK inhibitor. GSK 2606414 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR) like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival
US$ 141.26
US$ 126.47
US$ 141.26
US$ 1069.12
US$ 137.54
US$ 126.47
US$ 164.40
US$ 144.00
US$ 126.47
US$ 3630.00
US$ 126.47
US$ 171.73
US$ 112.23